Rossouw In the News
The North American Menopause Society (NAMS) will present Los Angeles Biomedical Research Institute (LA BioMed) researcher Rowan T. Chlebowski, MD, PhD, with the 2014 NAMS Lippincott/Williams & Wilkins Menopause Journal Best Paper Award at its annual meeting in Washington, D.C. in October. Dr. Chlebowski is a researcher for the NHLBI-supported Women’s Health Initiative.
An in-depth analysis of final data from one of the Women’s Health Initiative (WHI) Postmenopausal Hormone Therapy Trials has found that the investment in WHI resulted in a return of $140 in net economic value for each dollar invested in the trial.
It has been credited with preventing thousands of cases of breast cancer. It has confounded medical experts on everything from diet to hormone therapy.
But the NHLBI-supported Women’s Health Initiative also has cut through some of the clutter of smaller medical studies that offer contradictory conclusions about what’s best for women’s health.
A new analysis of data from the NHLBI-supported Women's Health Initiative found that postmenopausal women who quit smoking reduced their risk of heart disease, regardless of whether they had diabetes.
We report the first prospective study of the associations of
acquired APC resistance and of TFPI levels with stroke, and
we examine whether PHT-induced changes in these factors
are associated with stroke risk in the WHI trials. We also
examine associations with major subgroups of stroke.
New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.
A diet low in fat could reduce the risk of ovarian cancer in healthy postmenopausal women, according to new results from the Women's Health Initiative (WHI) Dietary Modification Trial. Researchers found that after four years, women who decreased the amount of dietary fat they consumed were 40 percent less likely to develop ovarian cancer than women who followed normal dietary patterns. As expected, no effect was found during the first four years because preventive benefits on cancer often take many years to develop. Ovarian cancer affects about 1 in 60 U.S.
New results from a substudy of the Women's Health Initiative (WHI) Estrogen-Alone Trial show that younger postmenopausal women who take estrogen-alone hormone therapy have significantly less buildup of calcium plaque in their arteries compared to their peers who did not take hormone therapy. Coronary artery calcium is considered a marker for future risk of coronary artery disease.
MEDIA AVAILABILITY: NHLBI Awards 12 Women's Health Initiative Contracts to Study Genetic and Biological Markers of Common Diseases Affecting Postmenopausal Women
Estrogen-alone hormone therapy does not increase the risk of breast cancer in postmenopausal women, according to an updated analysis of the breast cancer findings of the Women's Health Initiative (WHI) Estrogen-Alone Trial.
The results contrast with the previously reported WHI Estrogen plus Progestin Trial, which found an increase in breast cancer over about 5 years among those taking combined hormone therapy.
Many of the nation's leading scientists and experts on women's health will join Women's Health Initiative (WHI) study participants February 28 - March 1, 2006 at the National Institutes of Health (NIH) campus in Bethesda, MD to celebrate the legacy and probe the findings and future directions of the WHI. The WHI is the largest and most comprehensive study of postmenopausal women's health ever conducted in the United States.
Results of the first study on the long-term effects of a dietary pattern low in fat and high in carbohydrates suggest that a low-fat eating pattern does not lead to weight gain. The new Women's Health Initiative (WHI) study examined the relationships between weight changes in postmenopausal women and specific changes in types of food eaten. Women in the intervention group were counseled to decrease fat intake to 20 percent of calories and to replace calories from fat with calories from vegetables, fruits, and grains (with an emphasis on whole grains) -- but were not told to cut calories.
A large, multi-center heart disease prevention study, part of the Women's Health Initiative (WHI), found that estrogen-alone hormone therapy had no effect on coronary heart disease risk but increased the risk of stroke for postmenopausal women. The study also found that estrogen-alone therapy significantly increased the risk of deep vein thrombosis, had no significant effect on the risk of breast or colorectal cancer, and reduced the risk of hip and other fractures.
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has stopped early a major clinical trial of the risks and benefits of combined estrogen and progestin in healthy menopausal women due to an increased risk of invasive breast cancer. The large multi-center trial, a component of the Women's Health Initiative (WHI), also found increases in coronary heart disease, stroke, and pulmonary embolism in study participants on estrogen plus progestin compared to women taking placebo pills.